Dihydroartemisinin Suppresses Colorectal Cancer Growth in Association with JAK2/STAT3 Signalling Modulation.
Huang Ju J, Zhang Yukun Y, Luo Jun J, Shi Zhengda Z et al.
Dihydroartemisinin (DHA), an active derivative of artemisinin, has anti-tumour potential, but its immunomodulatory effects in Colorectal Cancer (CRC) remain insufficiently defined. We investigated whether DHA suppresses CRC phenotypes in association with JAK2/STAT3 inhibition and altered immune-checkpoint- marker expression. HCT116 and RKO CRC cells were evaluated using CCK-8, colony formation, wound healing, Transwell migration, live/dead staining, qRT-PCR, western blotting, and pharmacological rescue assays. A total of 20 male C57BL/6 mice (6-8 weeks old; 22-25 grams) with AOM/DSS-induced CRC were allocated to control and DHA-treatment groups (n = 10 per group) to assess tumour burden, pathway-associated markers, checkpoint-marker expression and CD8+ cell presence in tumour tissue. DHA inhibited CRC cell proliferation and migration and promoted apoptosis, as indicated by reduced Bcl-2 and increased cleaved caspase-3. DHA reduced JAK2/STAT3 signalling and PD-L1/CD47 expression; these effects were partly counteracted by Coumermycin A1. in vivo, DHA reduced tumour burden, improved histological differentiation, reduced Ki-67, JAK2/STAT3, PD-L1 and CD47 staining, and was associated with increased intratumoural CD8+ cell staining. The findings support an association between DHA treatment and reduced JAK2/STAT3 signalling, lower immune-evasion marker expression, and increased CD8+ cell presence; functional activation of CD8+ cells was not directly assessed. DHA suppresses CRC progression in the models studied and modulates JAK2/STAT3-associated immune-evasion markers. These data support further preclinical evaluation of DHA as a potential adjunctive strategy for CRC.